Jiang Long, Huang Jia, Li Chongwu, Shen Yaofeng, Zhang Yonglun, Lu Shun, Luo Qingquan
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Department of Thoracic Surgery, Hubei Jianghan Oilfield General Hospital, Qianjiang 832003, China.
Transl Lung Cancer Res. 2020 Jun;9(3):803-806. doi: 10.21037/tlcr-20-517.
Lung cancer is the leading global cause of cancer-related deaths. Even for patients who receive multidimensional treatment, the prognosis for locally advanced lung cancer is poor. The outcomes of neoadjuvant immunotherapy have been encouraging in many types of cancer, and especially lung cancer. However, the prognoses of patients with initially unresectable non-small cell lung cancer (NSCLC) with T4 or bulky swollen N2 lymph nodes are still unsatisfying, and novel therapeutic modalities are desperately needed. Here, we present a case of a patient with initially unresectable NSCLC with T4 and bulky swollen N2 lymph nodes, and present the argument for neoadjuvant immuno-based therapeutic strategies as a reasonable option for such patients.
肺癌是全球癌症相关死亡的主要原因。即使对于接受多维治疗的患者，局部晚期肺癌的预后也很差。新辅助免疫疗法在多种癌症，尤其是肺癌中的治疗效果令人鼓舞。然而，初始不可切除的伴有T4或肿大N2淋巴结的非小细胞肺癌（NSCLC）患者的预后仍然不尽人意，因此迫切需要新的治疗方式。在此，我们报告一例初始不可切除的伴有T4和肿大N2淋巴结的NSCLC患者，并提出新辅助免疫治疗策略作为此类患者合理选择的依据。
